Company Page

Exobiosphere

Founders

Exobiosphere is the world's first contract research organization (CRO) dedicated to high-throughput drug discovery in space. The company operates the Orbital High-Throughput Screener (OHTS), a compact, automated microgravity platform capable of running over 2,000 experiments per mission across six 96-well plates. By leveraging the unique biological behaviors unlocked in microgravity, Exobiosphere enables pharmaceutical and biotech partners to create more accurate disease models, accelerate preclinical testing, and reduce late-stage clinical failures. The company has secured strategic partnerships with Cedars-Sinai, the Luxembourg Institute of Health, ElevationSpace, and holds a EUR 200K contract from the European Space Agency.

Company Founded in 2024